Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss
Defence Therapeutics Inc. (DTCFF) is exploring the potential of its Accum® technology to enhance the efficacy of GLP-1 agonists in treating obesity and type 2 diabetes. The company aims to develop a formulation that improves the in vivo stability, distribution, tolerability, and activity of GLP-1 analogs.
This initiative addresses the growing global obesity crisis, with over 4 billion people expected to be overweight or obese by 2035. Current GLP-1 analogs face challenges such as gastrointestinal side effects, injection management, and patient compliance. Defence's Accum® technology could potentially overcome these limitations by acting as a protective nanocarrier.
The GLP-1 receptor agonist market is projected to reach US$125 billion by 2033, highlighting the significant opportunity in this therapeutic area.
Defence Therapeutics Inc. (DTCFF) sta esplorando il potenziale della sua tecnologia Accum® per migliorare l'efficacia degli agonisti GLP-1 nel trattamento dell'obesità e del diabete di tipo 2. L'azienda punta a sviluppare una formulazione che migliori la stabilità in vivo, la distribuzione, la tollerabilità e l'attività degli analoghi del GLP-1.
Questa iniziativa affronta la crescente crisi globale dell'obesità, con oltre 4 miliardi di persone che si prevede saranno in sovrappeso o obese entro il 2035. Gli attuali analoghi del GLP-1 affrontano sfide come effetti collaterali gastrointestinali, gestione delle iniezioni e aderenza dei pazienti. La tecnologia Accum® di Defence potrebbe potenzialmente superare queste limitazioni fungendo da nanocarrier protettivo.
Il mercato degli agonisti del recettore GLP-1 è previsto raggiungere 125 miliardi di dollari USA entro il 2033, evidenziando l'importante opportunità in questo ambito terapeutico.
Defence Therapeutics Inc. (DTCFF) está explorando el potencial de su tecnología Accum® para mejorar la eficacia de los agonistas GLP-1 en el tratamiento de la obesidad y la diabetes tipo 2. La empresa tiene como objetivo desarrollar una formulación que mejore la estabilidad in vivo, distribución, tolerabilidad y actividad de los análogos de GLP-1.
Esta iniciativa aborda la creciente crisis global de obesidad, con más de 4 mil millones de personas que se espera que estén con sobrepeso u obesidad para 2035. Los actuales análogos de GLP-1 enfrentan desafíos como efectos secundarios gastrointestinales, manejo de inyecciones y cumplimiento del paciente. La tecnología Accum® de Defence podría superar potencialmente estas limitaciones actuando como un nanotransportador protector.
Se prevé que el mercado de agonistas del receptor GLP-1 alcance 125 mil millones de dólares estadounidenses para 2033, destacando la significativa oportunidad en esta área terapéutica.
Defence Therapeutics Inc. (DTCFF)는 비만 및 제2형 당뇨병 치료에 있어 GLP-1 작용제의 효능을 향상시키기 위해 자사의 Accum® 기술의 잠재력을 탐색하고 있습니다. 회사는 GLP-1 유사체의 인 비보 안정성, 분포, 내약성 및 활성을 개선하는 제형을 개발하는 것을 목표로 하고 있습니다.
이 이니셔티브는 2035년까지 40억 명 이상의 사람들이 과체중 또는 비만으로 예상되는 증가하는 세계 비만 위기에 대응합니다. 현재 GLP-1 유사체는 위장 부작용, 주사 관리 및 환자 순응도와 같은 문제에 직면해 있습니다. Defence의 Accum® 기술은 보호 나노 운반체로 작용하여 이러한 한계를 극복할 수 있을 것으로 보입니다.
GLP-1 수용체 작용제 시장은 2033년까지 1,250억 달러에 이를 것으로 예상되어 이 치료 영역에서 중요한 기회를 강조합니다.
Defence Therapeutics Inc. (DTCFF) explore le potentiel de sa technologie Accum® pour améliorer l'efficacité des agonistes GLP-1 dans le traitement de l'obésité et du diabète de type 2. L'entreprise vise à développer une formulation qui améliore la stabilité in vivo, la distribution, la tolérance et l'activité des analogues du GLP-1.
Cette initiative s'attaque à la croissante crise mondiale de l'obésité, avec plus de 4 milliards de personnes qui devraient être en surpoids ou obèses d'ici 2035. Les analogues actuels du GLP-1 font face à des défis tels que les effets secondaires gastro-intestinaux, la gestion des injections et l'adhésion des patients. La technologie Accum® de Defence pourrait potentiellement surmonter ces limitations en agissant comme un nanotransporteur protecteur.
Le marché des agonistes des récepteurs GLP-1 devrait atteindre 125 milliards de dollars américains d'ici 2033, soulignant l'importante opportunité dans ce domaine thérapeutique.
Defence Therapeutics Inc. (DTCFF) untersucht das Potenzial seiner Accum®-Technologie, um die Wirksamkeit von GLP-1-Agonisten bei der Behandlung von Fettleibigkeit und Typ-2-Diabetes zu verbessern. Das Unternehmen strebt die Entwicklung einer Formulierung an, die die in vivo-Stabilität, Verteilung, Verträglichkeit und Aktivität von GLP-1-Analoga verbessert.
Diese Initiative greift die wachsende globale Fettleibigkeitskrise auf, wobei bis 2035 über 4 Milliarden Menschen als übergewichtig oder fettleibig erwartet werden. Aktuelle GLP-1-Analoga stehen vor Herausforderungen wie gastrointestinale Nebenwirkungen, Injektionsmanagement und Patiententreue. Die Accum®-Technologie von Defence könnte diese Einschränkungen möglicherweise überwinden, indem sie als schützender Nanocarrier fungiert.
Der Markt für GLP-1-Rezeptoragonisten wird bis 2033 voraussichtlich 125 Milliarden US-Dollar erreichen, was auf die bedeutende Chance in diesem therapeutischen Bereich hinweist.
- Potential to improve GLP-1 agonist efficacy for obesity and diabetes treatment
- Addressing a large market with over 4 billion people affected by obesity or overweight by 2035
- Opportunity to enhance patient compliance and reduce treatment burden
- Tapping into a rapidly growing market projected to reach US$125 billion by 2033
- Current limitations of GLP-1 peptide analogs including gastrointestinal side effects and injection challenges
- Potential competition from established GLP-1 agonist manufacturers
- Uncertainty in the success of applying Accum® technology to GLP-1 delivery
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum® technology to increase the half-life and efficacity of the GLP-1 agonist as a treatment for obesity and related comorbidities (type 2 diabetes).
Obesity is one of the most urgent health challenges in the world with extensive comorbidities, such as type 2 diabetes, cardiovascular diseases, steatohepatitis and chronic kidney disease to name a few. Over four billion people - about
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
https://www.worldobesity.org/news/economic-impact-of-overweight-and-obesity-to-surpass-4-trillion-by-2035
Native GLP-1 has a very short half-life (~ 2 min) and is rapidly degraded by dipeptidyl peptidase-IV (DPP-4). Modified GLP-1 peptide analogs with improved stability have therefore been developed for therapeutic purposes. The first GLP-1 peptide analog approved as an anti-diabetic agent is exenatide. The half-life of exenatide after subcutaneous injection is ∼2-3 h, requiring two injections daily. Liraglutide is a human GLP-1 analog with a half-life of ∼13 h, making it suitable for a single daily administration. In the last few years, dulaglutide and semaglutide have become available; these are long-acting GLP-1 analogs with >100-hour half-lives and require a single weekly injection. Current limitations of GLP-1 peptide analogs include the tolerability of gastrointestinal side effects, challenges with managing injections, as well as costs and scalability of drug manufacturing. Furthermore, there are still patient populations whose glucose levels and body weight cannot be adequately controlled by current therapeutics. Unfortunately, while optimization of GLP-1 drugs has reduced injection frequency from daily to weekly, the treatment burden of weekly injection still led to poor patience compliance and the development of longer acting GLP-1 agonists still to be a need for the patient compliance.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329993/
https://link.springer.com/chapter/10.1007/5584_2020_496
https://www.sciencedirect.com/science/article/pii/S1262363623000526?via%3Dihub
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823535/
Defence is currently planning to develop a formulation incorporating the Accum® technology to improve in vivo stability, distribution, tolerability and activity of GLP-1 analogs by acting as a protector nanocarrier formulation.
According to GlobalData, the market for GLP-1 receptor agonists is growing at an "unprecedented" rate and by 2033 it will be worth more than US
https://www.biospace.com/glp-1-receptor-agonist-market-to-reach-125b-by-2033-globaldata
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220401
FAQ
What is Defence Therapeutics (DTCFF) investigating for diabetes and weight loss treatment?
How could Defence Therapeutics' Accum® technology improve GLP-1 agonist treatments?
What is the projected market size for GLP-1 receptor agonists by 2033?
What are the current limitations of GLP-1 peptide analogs that Defence Therapeutics (DTCFF) aims to address?
